Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MANISH SHARMA

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1790819332
CMS profile
1126262
Location
GRAND RAPIDS, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$1,855.50

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $1,837.50 2
Food and Beverage $18.00 1

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Aadi Bioscience, Inc. $1,837.50 2
Novartis Pharmaceuticals Corporation $18.00 1

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MANISH SHARMA

NPI 1790819332 · CMS profile ID 1126262

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

GRAND RAPIDS, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1790819332?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MANISH SHARMA, NPI 1790819332, CMS profile ID 1126262. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1790819332?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). MANISH SHARMA, NPI 1790819332, CMS profile ID 1126262. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1790819332?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
MANISH SHARMA, NPI 1790819332, CMS profile ID 1126262, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1790819332?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $1,855.50 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Aadi Bioscience, Inc. $1,312.5009/02/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1250853033 CMS
Novartis Pharmaceuticals Corporation $18.0007/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200524770 CMS
Aadi Bioscience, Inc. $525.0007/29/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1250853011 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $659.76 21
PY2020 $185.35 5
PY2021 $23.93 1
PY2022 $558.49 34
PY2023 $1,123.71 47
PY2024 $773.90 11
PY2025 $1,855.50 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $373.20 2
PY2025 Principal investigator $4,235,582.65 823
PY2024 Recipient $4,269.33 9
PY2024 Principal investigator $3,811,534.65 643
PY2023 Recipient $3,810.00 6
PY2023 Principal investigator $3,149,687.09 471
PY2022 Principal investigator $3,302,171.04 339
PY2021 Recipient $7,293.02 4
PY2021 Principal investigator $2,076,760.51 208
PY2020 Recipient $7,900.00 2
PY2020 Principal investigator $1,132,655.23 78
PY2019 Principal investigator $1,305,040.24 61

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

212 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,116.17 12/31/2021 Non-covered Recipient Entity
CANCER AND HEMATOLOGY
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation No dispute reported 06/30/2026 826456207
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,054.11 12/31/2021 Non-covered Recipient Entity
CANCER & HEMATOLOGY CENTERS OF WESTERN MICHIGAN
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation No dispute reported 06/30/2026 826465399
Principal investigator 1 GlaxoSmithKline, LLC. $2,067.00 12/31/2021 Non-covered Recipient Entity
START MIDWEST
AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD No dispute reported 06/30/2026 809539807
Principal investigator 1 Merck Sharp & Dohme Corporation $17,257.46 12/31/2021 Non-covered Recipient Entity
START MIDWEST
A Phase Ib Multi-center Clinical Study of Selumetinib MK-5618 in Combination with Pembrolizumab MK-3475 in Participants with Metastatic Solid Tumors No dispute reported 06/30/2026 848751623
Principal investigator 1 PFIZER INC. $7,508.70 12/31/2021 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 832559523
Principal investigator 1 GlaxoSmithKline, LLC. $1,800.00 12/29/2021 Non-covered Recipient Entity
START MIDWEST
AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD No dispute reported 06/30/2026 809521655
Principal investigator 1 PFIZER INC. $38,165.12 12/23/2021 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 832559513
Principal investigator 1 PFIZER INC. $6,521.71 12/23/2021 Non-covered Recipient Entity
SMART Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 832567137
Principal investigator 1 Epizyme, Inc., $36,699.43 12/17/2021 Non-covered Recipient Entity
START MIDWEST LLC
A PHASE 1, OPEN-LABEL MULTI-DOSE TWO-PART STUDY TO CHARACTERIZE THE EFFECTS OF A STRONG CYP3A4 INHIBITOR ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT (EPZ-6438), AND THE EFFECTS OF A STRONG CYP3A4 INDUCER ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT IN SUBJECTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 832340815
Principal investigator 1 Epizyme, Inc., $714.00 12/17/2021 Non-covered Recipient Entity
START MIDWEST LLC
A PHASE 1, OPEN-LABEL MULTI-DOSE TWO-PART STUDY TO CHARACTERIZE THE EFFECTS OF A STRONG CYP3A4 INHIBITOR ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT (EPZ-6438), AND THE EFFECTS OF A STRONG CYP3A4 INDUCER ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT IN SUBJECTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 832340821
Principal investigator 1 Epizyme, Inc., $1,312.00 12/17/2021 Non-covered Recipient Entity
START MIDWEST LLC
A PHASE 1, OPEN-LABEL MULTI-DOSE TWO-PART STUDY TO CHARACTERIZE THE EFFECTS OF A STRONG CYP3A4 INHIBITOR ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT (EPZ-6438), AND THE EFFECTS OF A STRONG CYP3A4 INDUCER ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT IN SUBJECTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 832340827
Principal investigator 1 PFIZER INC. $6,786.71 12/15/2021 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 832581801
Principal investigator 1 Theratechnologies Inc. $2,015.00 12/15/2021 Non-covered Recipient Entity
START Midwest
A Phase 1, Open-Label, Dose Escalation Study of TH1902 in Patients With Advanced Solid Tumors and Expansion in Patients With Triple Negative Breast Cancer (TNBC), Gynecological Cancer, Colorectal Cancer, and Pancreatic Cancer No dispute reported 06/30/2026 834909929
Principal investigator 1 PFIZER INC. $7,756.24 12/14/2021 Non-covered Recipient Entity
START Midwest
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 832580639
Principal investigator 1 PFIZER INC. $45.00 12/14/2021 Non-covered Recipient Entity
START Midwest
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 832580927
Principal investigator 1 Exelixis Inc. $40.50 12/10/2021 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838857187
Principal investigator 1 Exelixis Inc. $1,606.50 12/10/2021 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838857189
Principal investigator 1 Exelixis Inc. $349.33 12/10/2021 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838857191
Principal investigator 1 Exelixis Inc. $860.00 12/10/2021 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838857193
Principal investigator 1 Exelixis Inc. $337.50 12/10/2021 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838857195
Principal investigator 1 MACROGENICS, INC. $5,032.89 12/10/2021 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 838715047
Principal investigator 1 MACROGENICS, INC. $2,141.66 12/10/2021 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 838715053
Principal investigator 1 MACROGENICS, INC. $3,533.73 12/10/2021 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 838715057
Principal investigator 1 PFIZER INC. $10,455.70 12/08/2021 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 832559097
Principal investigator 1 PFIZER INC. $10,798.50 12/08/2021 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 832566327
Principal investigator 1 PFIZER INC. $5,407.55 12/07/2021 Non-covered Recipient Entity
SMART Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 832567147
Principal investigator 1 Epizyme, Inc., $100.00 12/03/2021 Non-covered Recipient Entity
START MIDWEST LLC
A PHASE 1, OPEN-LABEL MULTI-DOSE TWO-PART STUDY TO CHARACTERIZE THE EFFECTS OF A STRONG CYP3A4 INHIBITOR ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT (EPZ-6438), AND THE EFFECTS OF A STRONG CYP3A4 INDUCER ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT IN SUBJECTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 832340673
Principal investigator 1 Epizyme, Inc., $1,428.00 12/03/2021 Non-covered Recipient Entity
START MIDWEST LLC
A PHASE 1, OPEN-LABEL MULTI-DOSE TWO-PART STUDY TO CHARACTERIZE THE EFFECTS OF A STRONG CYP3A4 INHIBITOR ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT (EPZ-6438), AND THE EFFECTS OF A STRONG CYP3A4 INDUCER ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT IN SUBJECTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 832340679
Principal investigator 1 Epizyme, Inc., $238.00 12/03/2021 Non-covered Recipient Entity
START MIDWEST LLC
A PHASE 1, OPEN-LABEL MULTI-DOSE TWO-PART STUDY TO CHARACTERIZE THE EFFECTS OF A STRONG CYP3A4 INHIBITOR ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT (EPZ-6438), AND THE EFFECTS OF A STRONG CYP3A4 INDUCER ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT IN SUBJECTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 832340685
Principal investigator 1 Epizyme, Inc., $952.00 12/03/2021 Non-covered Recipient Entity
START MIDWEST LLC
A PHASE 1, OPEN-LABEL MULTI-DOSE TWO-PART STUDY TO CHARACTERIZE THE EFFECTS OF A STRONG CYP3A4 INHIBITOR ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT (EPZ-6438), AND THE EFFECTS OF A STRONG CYP3A4 INDUCER ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT IN SUBJECTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 832340693
Principal investigator 1 Epizyme, Inc., $1,280.00 12/03/2021 Non-covered Recipient Entity
START MIDWEST LLC
A PHASE 1, OPEN-LABEL MULTI-DOSE TWO-PART STUDY TO CHARACTERIZE THE EFFECTS OF A STRONG CYP3A4 INHIBITOR ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT (EPZ-6438), AND THE EFFECTS OF A STRONG CYP3A4 INDUCER ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT IN SUBJECTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 832340697
Principal investigator 1 Epizyme, Inc., $238.00 12/03/2021 Non-covered Recipient Entity
START MIDWEST LLC
A PHASE 1, OPEN-LABEL MULTI-DOSE TWO-PART STUDY TO CHARACTERIZE THE EFFECTS OF A STRONG CYP3A4 INHIBITOR ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT (EPZ-6438), AND THE EFFECTS OF A STRONG CYP3A4 INDUCER ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT IN SUBJECTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 832340705
Principal investigator 1 Epizyme, Inc., $350.00 12/03/2021 Non-covered Recipient Entity
START MIDWEST LLC
A PHASE 1, OPEN-LABEL MULTI-DOSE TWO-PART STUDY TO CHARACTERIZE THE EFFECTS OF A STRONG CYP3A4 INHIBITOR ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT (EPZ-6438), AND THE EFFECTS OF A STRONG CYP3A4 INDUCER ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT IN SUBJECTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 832340709
Principal investigator 1 PFIZER INC. $93,614.40 12/02/2021 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 832559503
Principal investigator 1 PFIZER INC. $90.00 12/02/2021 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 832577721
Principal investigator 1 PFIZER INC. $4,847.65 12/02/2021 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 832580655
Principal investigator 1 MACROGENICS, INC. $380.00 11/30/2021 Non-covered Recipient Entity
CANCER AND HEMATOLOGY CENTERS
COMBINATION MARGETUXIMAB, INCMGA00012, MGD013, AND CHEMOTHERAPY PHASE 2 3 TRIAL IN HER2 GASTRIC GEJ CANCER MAHOGANY No dispute reported 06/30/2026 838714911
Principal investigator 1 GlaxoSmithKline, LLC. $8,562.00 11/29/2021 Non-covered Recipient Entity
START MIDWEST
AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD No dispute reported 06/30/2026 809521817
Principal investigator 1 PFIZER INC. $11,997.16 11/23/2021 Non-covered Recipient Entity
SMART Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 832765003
Principal investigator 1 PFIZER INC. $24,997.97 11/23/2021 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 832884709
Principal investigator 1 Exelixis Inc. $375.00 11/19/2021 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838856861
Principal investigator 1 Exelixis Inc. $510.30 11/19/2021 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838856863
Principal investigator 1 Exelixis Inc. $564.30 11/19/2021 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838856865
Principal investigator 1 Exelixis Inc. $74.25 11/15/2021 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838856917
Principal investigator 1 Exelixis Inc. $561.00 11/15/2021 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838856919
Principal investigator 1 Exelixis Inc. $675.00 11/15/2021 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838856921
Principal investigator 1 MACROGENICS, INC. $596.13 11/15/2021 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS MIDWEST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 838714637
Principal investigator 1 PFIZER INC. $16,315.44 11/10/2021 Non-covered Recipient Entity
START Midwest
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 832578631
Principal investigator 1 PFIZER INC. $12,676.50 11/10/2021 Non-covered Recipient Entity
START Midwest
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 832580333
Principal investigator 1 PFIZER INC. $5,817.18 11/08/2021 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 832580937
Principal investigator 1 PFIZER INC. $27.00 11/08/2021 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 832581518
Principal investigator 1 Exelixis Inc. $74.25 11/05/2021 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838856827
Principal investigator 1 PFIZER INC. $4,434.42 11/05/2021 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 832823741
Principal investigator 1 PFIZER INC. $833.00 11/05/2021 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 832916505
Principal investigator 1 GlaxoSmithKline, LLC. $2,116.00 11/01/2021 Non-covered Recipient Entity
START MIDWEST
AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD No dispute reported 06/30/2026 809521811
Principal investigator 1 Epizyme, Inc., $831.00 10/28/2021 Non-covered Recipient Entity
START MIDWEST LLC
A PHASE 1, OPEN-LABEL MULTI-DOSE TWO-PART STUDY TO CHARACTERIZE THE EFFECTS OF A STRONG CYP3A4 INHIBITOR ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT (EPZ-6438), AND THE EFFECTS OF A STRONG CYP3A4 INDUCER ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT IN SUBJECTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 832340377
Principal investigator 1 GlaxoSmithKline, LLC. $1,300.00 10/27/2021 Non-covered Recipient Entity
START MIDWEST
AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD No dispute reported 06/30/2026 809521649
Principal investigator 1 PFIZER INC. $537.75 10/22/2021 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 832689821
Principal investigator 1 PFIZER INC. $3,229.80 10/21/2021 Non-covered Recipient Entity
SMART Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 832822849
Principal investigator 1 PFIZER INC. $969.53 10/20/2021 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 832580327
Principal investigator 1 PFIZER INC. $12,676.50 10/19/2021 Non-covered Recipient Entity
START Midwest
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 832578639
Principal investigator 1 PFIZER INC. $12,236.58 10/19/2021 Non-covered Recipient Entity
START Midwest
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 832581527
Principal investigator 1 Exelixis Inc. $40.50 10/13/2021 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838856627
Principal investigator 1 Exelixis Inc. $612.00 10/13/2021 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838856629
Principal investigator 1 Exelixis Inc. $650.00 10/13/2021 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838856631
Principal investigator 1 Exelixis Inc. $448.20 10/13/2021 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838856633
Principal investigator 1 Exelixis Inc. $675.00 10/13/2021 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838856635
Principal investigator 1 Exelixis Inc. $1,615.55 10/13/2021 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838856637
Principal investigator 1 Exelixis Inc. $891.00 10/13/2021 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838856639
Principal investigator 1 Exelixis Inc. $788.40 10/13/2021 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838856641
Principal investigator 1 Exelixis Inc. $612.00 10/13/2021 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838856687
Principal investigator 1 Exelixis Inc. $5,250.00 10/13/2021 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838856689
Principal investigator 1 Exelixis Inc. $224.10 10/13/2021 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838856691
Principal investigator 1 Exelixis Inc. $1,687.50 10/13/2021 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838856693
Principal investigator 1 PFIZER INC. $18.00 10/13/2021 Non-covered Recipient Entity
START Midwest
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 832577731
Principal investigator 1 Theratechnologies Inc. $8,950.00 10/13/2021 Non-covered Recipient Entity
START Midwest
A Phase 1, Open-Label, Dose Escalation Study of TH1902 in Patients With Advanced Solid Tumors and Expansion in Patients With Triple Negative Breast Cancer (TNBC), Gynecological Cancer, Colorectal Cancer, and Pancreatic Cancer No dispute reported 06/30/2026 834909927
Principal investigator 1 PFIZER INC. $3,878.12 10/12/2021 Non-covered Recipient Entity
START Midwest
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 832580947
Principal investigator 1 MACROGENICS, INC. $400.02 10/11/2021 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 838713865
Principal investigator 1 PFIZER INC. $21,786.10 10/09/2021 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 832782147
Principal investigator 1 Exelixis Inc. $21,168.94 10/08/2021 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838856597
Principal investigator 1 PFIZER INC. $15,761.26 10/08/2021 Non-covered Recipient Entity
SMART Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 832754421
Principal investigator 1 PFIZER INC. $2,410.00 10/08/2021 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 832757455
Principal investigator 1 MACROGENICS, INC. $130.00 10/04/2021 Non-covered Recipient Entity
START MIDWEST LLC
MGC018 WITH OR WITHOUT MGA012 IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 838713649
Principal investigator 1 Merck Sharp & Dohme Corporation $91,000.00 10/04/2021 Non-covered Recipient Entity
START MIDWEST
An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX 106 in Subjects with Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 848765925
Principal investigator 1 GlaxoSmithKline, LLC. $40,664.00 09/30/2021 Non-covered Recipient Entity
START MIDWEST
AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD No dispute reported 06/30/2026 809529485
Principal investigator 1 PFIZER INC. $12,236.58 09/29/2021 Non-covered Recipient Entity
START Midwest
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 832577741
Principal investigator 1 PFIZER INC. $12,676.50 09/29/2021 Non-covered Recipient Entity
START Midwest
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 832579997
Principal investigator 1 MACROGENICS, INC. $2,138.00 09/27/2021 Non-covered Recipient Entity
START MIDWEST LLC
MGC018 WITH OR WITHOUT MGA012 IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 838713437
Principal investigator 1 PFIZER INC. $300.00 09/22/2021 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 832733303
Principal investigator 1 PFIZER INC. $4,290.30 09/22/2021 Non-covered Recipient Entity
SMART Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 832738675
Principal investigator 1 PFIZER INC. $9,986.63 09/22/2021 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 832873834
Principal investigator 1 Theratechnologies Inc. $18,050.00 09/22/2021 Non-covered Recipient Entity
START Midwest
A Phase 1, Open-Label, Dose Escalation Study of TH1902 in Patients With Advanced Solid Tumors and Expansion in Patients With Triple Negative Breast Cancer (TNBC), Gynecological Cancer, Colorectal Cancer, and Pancreatic Cancer No dispute reported 06/30/2026 834909925
Principal investigator 1 PFIZER INC. $1,939.06 09/15/2021 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 832581509
Principal investigator 1 MACROGENICS, INC. $251.03 09/10/2021 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 838713301
Principal investigator 1 Exelixis Inc. $25,715.41 09/08/2021 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838854359
Principal investigator 1 PFIZER INC. $2,400.30 09/04/2021 Non-covered Recipient Entity
SMART Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 832733297
Principal investigator 1 PFIZER INC. $9,172.59 09/04/2021 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 832757693
Principal investigator 1 PFIZER INC. $3,369.70 09/04/2021 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 832879825
Principal investigator 1 GlaxoSmithKline, LLC. $359.10 09/03/2021 Non-covered Recipient Entity
START MIDWEST
AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD No dispute reported 06/30/2026 809489543
Principal investigator 1 PFIZER INC. $16,315.44 08/30/2021 Non-covered Recipient Entity
START Midwest
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 832581795
Principal investigator 1 PFIZER INC. $2,908.59 08/23/2021 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 832580017
Principal investigator 1 PFIZER INC. $314.55 08/21/2021 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 832689655
Principal investigator 1 PFIZER INC. $507.00 08/21/2021 Non-covered Recipient Entity
SMART Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 832789133
Principal investigator 1 PFIZER INC. $20,047.88 08/21/2021 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 832884695
Principal investigator 1 Epizyme, Inc., $2,100.00 08/13/2021 Non-covered Recipient Entity
START MIDWEST LLC
A PHASE 1, OPEN-LABEL MULTI-DOSE TWO-PART STUDY TO CHARACTERIZE THE EFFECTS OF A STRONG CYP3A4 INHIBITOR ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT (EPZ-6438), AND THE EFFECTS OF A STRONG CYP3A4 INDUCER ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT IN SUBJECTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 832340025
Principal investigator 1 Epizyme, Inc., $350.00 08/13/2021 Non-covered Recipient Entity
START MIDWEST LLC
A PHASE 1, OPEN-LABEL MULTI-DOSE TWO-PART STUDY TO CHARACTERIZE THE EFFECTS OF A STRONG CYP3A4 INHIBITOR ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT (EPZ-6438), AND THE EFFECTS OF A STRONG CYP3A4 INDUCER ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT IN SUBJECTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 832340031
Principal investigator 1 Epizyme, Inc., $350.00 08/13/2021 Non-covered Recipient Entity
START MIDWEST LLC
A PHASE 1, OPEN-LABEL MULTI-DOSE TWO-PART STUDY TO CHARACTERIZE THE EFFECTS OF A STRONG CYP3A4 INHIBITOR ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT (EPZ-6438), AND THE EFFECTS OF A STRONG CYP3A4 INDUCER ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT IN SUBJECTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 832340037
Principal investigator 1 Epizyme, Inc., $350.00 08/13/2021 Non-covered Recipient Entity
START MIDWEST LLC
A PHASE 1, OPEN-LABEL MULTI-DOSE TWO-PART STUDY TO CHARACTERIZE THE EFFECTS OF A STRONG CYP3A4 INHIBITOR ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT (EPZ-6438), AND THE EFFECTS OF A STRONG CYP3A4 INDUCER ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT IN SUBJECTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 832340043
Principal investigator 1 Epizyme, Inc., $119.00 08/13/2021 Non-covered Recipient Entity
START MIDWEST LLC
A PHASE 1, OPEN-LABEL MULTI-DOSE TWO-PART STUDY TO CHARACTERIZE THE EFFECTS OF A STRONG CYP3A4 INHIBITOR ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT (EPZ-6438), AND THE EFFECTS OF A STRONG CYP3A4 INDUCER ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT IN SUBJECTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 832340049
Principal investigator 1 Epizyme, Inc., $3,922.60 08/13/2021 Non-covered Recipient Entity
START MIDWEST LLC
A PHASE 1, OPEN-LABEL MULTI-DOSE TWO-PART STUDY TO CHARACTERIZE THE EFFECTS OF A STRONG CYP3A4 INHIBITOR ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT (EPZ-6438), AND THE EFFECTS OF A STRONG CYP3A4 INDUCER ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT IN SUBJECTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 832340055
Principal investigator 1 PFIZER INC. $12,236.58 08/11/2021 Non-covered Recipient Entity
START Midwest
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 832580343
Principal investigator 1 PFIZER INC. $25,353.00 08/11/2021 Non-covered Recipient Entity
START Midwest
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 832581237
Principal investigator 1 MACROGENICS, INC. $277.51 08/10/2021 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 838712913
Principal investigator 1 PFIZER INC. $508.95 08/06/2021 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 832704035
Principal investigator 1 PFIZER INC. $2,501.55 08/06/2021 Non-covered Recipient Entity
SMART Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 832706609
Principal investigator 1 PFIZER INC. $21,243.29 08/06/2021 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 832815043
Principal investigator 1 MACROGENICS, INC. $208.00 08/04/2021 Non-covered Recipient Entity
START MIDWEST LLC
MGC018 WITH OR WITHOUT MGA012 IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 838712825
Principal investigator 1 Merck Sharp & Dohme Corporation $25,823.10 08/04/2021 Non-covered Recipient Entity
START MIDWEST
A Phase Ib Multi-center Clinical Study of Selumetinib MK-5618 in Combination with Pembrolizumab MK-3475 in Participants with Metastatic Solid Tumors No dispute reported 06/30/2026 848751621
Principal investigator 1 Epizyme, Inc., $137,207.69 07/28/2021 Non-covered Recipient Entity
START MIDWEST LLC
A PHASE 1, OPEN-LABEL MULTI-DOSE TWO-PART STUDY TO CHARACTERIZE THE EFFECTS OF A STRONG CYP3A4 INHIBITOR ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT (EPZ-6438), AND THE EFFECTS OF A STRONG CYP3A4 INDUCER ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT IN SUBJECTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 832339727
Principal investigator 1 PFIZER INC. $18.00 07/27/2021 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 832578649
Principal investigator 1 PFIZER INC. $3,878.12 07/27/2021 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 832581247
Principal investigator 1 MACROGENICS, INC. $202.50 07/21/2021 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 838712575
Principal investigator 1 PFIZER INC. $26,715.52 07/21/2021 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 832709203
Principal investigator 1 PFIZER INC. $3,518.10 07/21/2021 Non-covered Recipient Entity
SMART Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 832906293
Principal investigator 1 PFIZER INC. $25,353.00 07/14/2021 Non-covered Recipient Entity
START Midwest
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 832579401
Principal investigator 1 PFIZER INC. $12,236.58 07/14/2021 Non-covered Recipient Entity
START Midwest
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 832580647
Principal investigator 1 PFIZER INC. $8,157.72 07/12/2021 Non-covered Recipient Entity
START Midwest
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 832580007
Principal investigator 1 PFIZER INC. $774.00 07/09/2021 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 832736127
Principal investigator 1 PFIZER INC. $5,206.85 07/09/2021 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 832800335
Principal investigator 1 PFIZER INC. $1,759.05 07/09/2021 Non-covered Recipient Entity
SMART Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 832812455
Principal investigator 1 GlaxoSmithKline, LLC. $5,456.00 07/07/2021 Non-covered Recipient Entity
START MIDWEST
AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD No dispute reported 06/30/2026 809496839
Principal investigator 1 Exelixis Inc. $20,163.46 07/02/2021 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838853715
Principal investigator 1 Exelixis Inc. $1,871.10 06/25/2021 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838853093
Principal investigator 1 Exelixis Inc. $148.50 06/25/2021 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838853095
Principal investigator 1 Exelixis Inc. $4,054.50 06/25/2021 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838853097
Principal investigator 1 Exelixis Inc. $112.05 06/25/2021 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838853099
Principal investigator 1 Exelixis Inc. $2,751.30 06/25/2021 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838853101
Principal investigator 1 Exelixis Inc. $600.00 06/25/2021 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838853103
Principal investigator 1 Exelixis Inc. $337.50 06/25/2021 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838853105
Principal investigator 1 Exelixis Inc. $2,382.75 06/25/2021 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838853107
Principal investigator 1 PFIZER INC. $11,125.43 06/23/2021 Non-covered Recipient Entity
SMART Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 832712285
Principal investigator 1 PFIZER INC. $12,676.50 06/22/2021 Non-covered Recipient Entity
START Midwest
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 832689729
Principal investigator 1 PFIZER INC. $12,236.58 06/22/2021 Non-covered Recipient Entity
START Midwest
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 832761769
Principal investigator 1 PFIZER INC. $750.00 06/22/2021 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 832806273
Principal investigator 1 MACROGENICS, INC. $12,427.04 06/21/2021 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 838712195
Principal investigator 1 MACROGENICS, INC. $5,288.10 06/21/2021 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 838712201
Principal investigator 1 MACROGENICS, INC. $8,725.37 06/21/2021 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 838712207
Principal investigator 1 GlaxoSmithKline, LLC. $21,125.00 06/17/2021 Non-covered Recipient Entity
START MIDWEST
AN OPEN-LABEL, MULTICENTER, LONG-TERM TREATMENT EXTENSION STUDY IN SUB No dispute reported 06/30/2026 860868903
Principal investigator 1 Exelixis Inc. $27,172.33 06/11/2021 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838853027
Principal investigator 1 PFIZER INC. $7,421.29 06/05/2021 Non-covered Recipient Entity
SMART Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 832782775
Principal investigator 1 PFIZER INC. $4,262.30 06/05/2021 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 832795967
Principal investigator 1 MACROGENICS, INC. $208.00 06/03/2021 Non-covered Recipient Entity
START MIDWEST LLC
MGC018 WITH OR WITHOUT MGA012 IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 838712003
Principal investigator 1 Eli Lilly and Company $236.70 05/26/2021 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS LLC
A PHASE 1 MULTICENTER GLOBAL FIRST IN HUMAN STUDY OF THE CD73 INHIBITOR LY3475070 AS MONOTHERAPY OR IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES No dispute reported 06/30/2026 819468875
Principal investigator 1 PFIZER INC. $18,354.87 05/24/2021 Non-covered Recipient Entity
START Midwest
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 832705573
Principal investigator 1 PFIZER INC. $25,353.00 05/24/2021 Non-covered Recipient Entity
START Midwest
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 832882291
Principal investigator 1 PFIZER INC. $1,513.35 05/21/2021 Non-covered Recipient Entity
SMART Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 832732381
Principal investigator 1 MACROGENICS, INC. $1,933.96 05/20/2021 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 838711809
Principal investigator 1 MACROGENICS, INC. $822.96 05/20/2021 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 838711815
Principal investigator 1 MACROGENICS, INC. $1,357.88 05/20/2021 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 838711821
Principal investigator 1 Exelixis Inc. $15,216.86 05/14/2021 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838852651
Principal investigator 1 Exelixis Inc. $14,693.60 05/10/2021 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838852781
Principal investigator 1 Exelixis Inc. $224.10 05/10/2021 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838852795
Principal investigator 1 PFIZER INC. $26,050.00 05/08/2021 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 832835645
Principal investigator 1 PFIZER INC. $8,363.28 05/08/2021 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 832855941
Principal investigator 1 PFIZER INC. $3,968.00 05/07/2021 Non-covered Recipient Entity
SMART Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 832891755
Principal investigator 1 Exelixis Inc. $1,670.00 04/21/2021 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838852393
Principal investigator 1 PFIZER INC. $3,355.42 04/21/2021 Non-covered Recipient Entity
SMART Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 832823483
Principal investigator 1 Exelixis Inc. $106,664.24 04/09/2021 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838852451
Principal investigator 1 PFIZER INC. $9,998.78 04/09/2021 Non-covered Recipient Entity
SMART Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 832818301
Recipient MacroGenics, Inc. $2,294.43 04/07/2021 Covered Recipient Physician MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 838711333
Recipient MacroGenics, Inc. $976.35 04/07/2021 Covered Recipient Physician MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 838711339
Recipient MacroGenics, Inc. $1,610.98 04/07/2021 Covered Recipient Physician MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 838711345
Principal investigator 1 GlaxoSmithKline, LLC. $1,364.00 03/31/2021 Non-covered Recipient Entity
START MIDWEST
AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD No dispute reported 06/30/2026 809496915
Principal investigator 1 MACROGENICS, INC. $5,232.42 03/24/2021 Non-covered Recipient Entity
START MIDWEST LLC
MGD009 MGA012 COMBINATION IN RELAPSED REFRACTORY CANCER No dispute reported 06/30/2026 838711011
Principal investigator 1 PFIZER INC. $9,354.50 03/24/2021 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 832801209
Principal investigator 1 PFIZER INC. $3,100.30 03/24/2021 Non-covered Recipient Entity
SMART Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 832903477
Principal investigator 1 MACROGENICS, INC. $4,159.21 03/23/2021 Non-covered Recipient Entity
START MIDWEST LLC
MGD009 MGA012 COMBINATION IN RELAPSED REFRACTORY CANCER No dispute reported 06/30/2026 838711005
Principal investigator 1 Epizyme, Inc., $290.00 03/17/2021 Non-covered Recipient Entity
START MIDWEST LLC
A PHASE 1, OPEN-LABEL MULTI-DOSE TWO-PART STUDY TO CHARACTERIZE THE EFFECTS OF A STRONG CYP3A4 INHIBITOR ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT (EPZ-6438), AND THE EFFECTS OF A STRONG CYP3A4 INDUCER ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT IN SUBJECTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 832338921
Principal investigator 1 MACROGENICS, INC. $2,569.50 03/17/2021 Non-covered Recipient Entity
START MIDWEST LLC
MGD009 MGA012 COMBINATION IN RELAPSED REFRACTORY CANCER No dispute reported 06/30/2026 838710849
Principal investigator 1 MACROGENICS, INC. $847.41 03/09/2021 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 838710715
Principal investigator 1 MACROGENICS, INC. $360.60 03/09/2021 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 838710721
Principal investigator 1 MACROGENICS, INC. $594.99 03/09/2021 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 838710727
Principal investigator 1 MACROGENICS, INC. $4,800.00 03/08/2021 Non-covered Recipient Entity
START MIDWEST LLC
MGD009 MGA012 COMBINATION IN RELAPSED REFRACTORY CANCER No dispute reported 06/30/2026 838710525
Principal investigator 1 PFIZER INC. $3,965.00 03/06/2021 Non-covered Recipient Entity
SMART Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 832801883
Principal investigator 1 Exelixis Inc. $3,390.00 03/05/2021 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838850221
Principal investigator 1 Exelixis Inc. $1,910.25 03/05/2021 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838850223
Principal investigator 1 MACROGENICS, INC. $150.00 03/01/2021 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 838710251
Principal investigator 1 MACROGENICS, INC. $130.00 03/01/2021 Non-covered Recipient Entity
START MIDWEST LLC
MGC018 WITH OR WITHOUT MGA012 IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 838710257
Principal investigator 1 MACROGENICS, INC. $660.00 03/01/2021 Non-covered Recipient Entity
START MIDWEST LLC
MGD009 MGA012 COMBINATION IN RELAPSED REFRACTORY CANCER No dispute reported 06/30/2026 838710263
Principal investigator 1 AstraZeneca Pharmaceuticals LP $17,620.16 02/26/2021 Non-covered Recipient Entity
CANCER AND HEMATOLOGY
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation No dispute reported 06/30/2026 826493745
Principal investigator 1 AstraZeneca Pharmaceuticals LP $16,640.44 02/26/2021 Non-covered Recipient Entity
CANCER & HEMATOLOGY CENTERS OF WESTERN MICHIGAN
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation No dispute reported 06/30/2026 826503527
Principal investigator 1 MACROGENICS, INC. $3,262.75 02/26/2021 Non-covered Recipient Entity
START MIDWEST LLC
MGD009 MGA012 COMBINATION IN RELAPSED REFRACTORY CANCER No dispute reported 06/30/2026 838710191
Principal investigator 1 PFIZER INC. $76,831.22 02/24/2021 Non-covered Recipient Entity
SMART Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 832878653
Principal investigator 1 Epizyme, Inc., $100.00 02/22/2021 Non-covered Recipient Entity
START MIDWEST LLC
A PHASE 1, OPEN-LABEL MULTI-DOSE TWO-PART STUDY TO CHARACTERIZE THE EFFECTS OF A STRONG CYP3A4 INHIBITOR ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT (EPZ-6438), AND THE EFFECTS OF A STRONG CYP3A4 INDUCER ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT IN SUBJECTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 832338755
Principal investigator 1 Epizyme, Inc., $100.00 02/22/2021 Non-covered Recipient Entity
START MIDWEST LLC
A PHASE 1, OPEN-LABEL MULTI-DOSE TWO-PART STUDY TO CHARACTERIZE THE EFFECTS OF A STRONG CYP3A4 INHIBITOR ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT (EPZ-6438), AND THE EFFECTS OF A STRONG CYP3A4 INDUCER ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT IN SUBJECTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 832338761
Principal investigator 1 Epizyme, Inc., $350.00 02/22/2021 Non-covered Recipient Entity
START MIDWEST LLC
A PHASE 1, OPEN-LABEL MULTI-DOSE TWO-PART STUDY TO CHARACTERIZE THE EFFECTS OF A STRONG CYP3A4 INHIBITOR ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT (EPZ-6438), AND THE EFFECTS OF A STRONG CYP3A4 INDUCER ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT IN SUBJECTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 832338767
Principal investigator 1 Epizyme, Inc., $4,070.00 02/22/2021 Non-covered Recipient Entity
START MIDWEST LLC
A PHASE 1, OPEN-LABEL MULTI-DOSE TWO-PART STUDY TO CHARACTERIZE THE EFFECTS OF A STRONG CYP3A4 INHIBITOR ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT (EPZ-6438), AND THE EFFECTS OF A STRONG CYP3A4 INDUCER ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT IN SUBJECTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 832338773
Principal investigator 1 MACROGENICS, INC. $75.01 02/19/2021 Non-covered Recipient Entity
START MIDWEST LLC
MGD009 MGA012 COMBINATION IN RELAPSED REFRACTORY CANCER No dispute reported 06/30/2026 838710103
Principal investigator 1 MACROGENICS, INC. $5,234.31 02/09/2021 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 838709787
Principal investigator 1 MACROGENICS, INC. $2,227.37 02/09/2021 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 838709793
Principal investigator 1 MACROGENICS, INC. $3,675.15 02/09/2021 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 838709799
Principal investigator 1 MACROGENICS, INC. $75.00 02/01/2021 Non-covered Recipient Entity
START MIDWEST LLC
MGC018 WITH OR WITHOUT MGA012 IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 838709479
Recipient Eli Lilly and Company $2,411.26 01/26/2021 Covered Recipient Physician A PHASE 1 MULTICENTER GLOBAL FIRST IN HUMAN STUDY OF THE CD73 INHIBITOR LY3475070 AS MONOTHERAPY OR IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES No dispute reported 06/30/2026 819445187
Principal investigator 1 GlaxoSmithKline, LLC. $1,200.00 01/26/2021 Non-covered Recipient Entity
START MIDWEST
AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD No dispute reported 06/30/2026 809489737
Principal investigator 1 MACROGENICS, INC. $1,356.75 01/15/2021 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 838709219
Principal investigator 1 MACROGENICS, INC. $43,609.18 01/14/2021 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 838709155
Principal investigator 1 MACROGENICS, INC. $18,557.10 01/14/2021 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 838709161
Principal investigator 1 MACROGENICS, INC. $30,619.22 01/14/2021 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 838709165
Principal investigator 1 GlaxoSmithKline, LLC. $21,050.00 01/12/2021 Non-covered Recipient Entity
START MIDWEST
AN OPEN-LABEL, MULTICENTER, LONG-TERM TREATMENT EXTENSION STUDY IN SUB No dispute reported 06/30/2026 809484245
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $220,675.49 01/08/2021 Non-covered Recipient Entity
Start Midwest
Phase I II TIM3 FIH Monotherapy Nivo Combination in advanced solid tumors No dispute reported 06/30/2026 819901301
Principal investigator 1 Epizyme, Inc., $300.00 01/05/2021 Non-covered Recipient Entity
START MIDWEST LLC
A PHASE 1, OPEN-LABEL MULTI-DOSE TWO-PART STUDY TO CHARACTERIZE THE EFFECTS OF A STRONG CYP3A4 INHIBITOR ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT (EPZ-6438), AND THE EFFECTS OF A STRONG CYP3A4 INDUCER ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT IN SUBJECTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 832338367
Principal investigator 1 Eli Lilly and Company $84,282.40 01/04/2021 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS LLC
A PHASE 1 MULTICENTER GLOBAL FIRST IN HUMAN STUDY OF THE CD73 INHIBITOR LY3475070 AS MONOTHERAPY OR IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES No dispute reported 06/30/2026 819468871